125 related articles for article (PubMed ID: 9159534)
1. High prolactin and low dehydroepiandrosterone sulphate serum levels in patients with severe systemic sclerosis.
Straub RH; Zeuner M; Lock G; Schölmerich J; Lang B
Br J Rheumatol; 1997 Apr; 36(4):426-32. PubMed ID: 9159534
[TBL] [Abstract][Full Text] [Related]
2. In polymyalgia rheumatica serum prolactin is positively correlated with the number of typical symptoms but not with typical inflammatory markers.
Straub RH; Georgi J; Helmke K; Vaith P; Lang B
Rheumatology (Oxford); 2002 Apr; 41(4):423-9. PubMed ID: 11961173
[TBL] [Abstract][Full Text] [Related]
3. Dehydroepiandrosterone sulphate serum levels in systemic sclerosis.
La Montagna G; Baruffo A; Buono G; Valentini G
Clin Exp Rheumatol; 2001; 19(1):21-6. PubMed ID: 11247320
[TBL] [Abstract][Full Text] [Related]
4. Bioactivity of prolactin in systemic sclerosis.
La Montagna G; Meli R; Criscuolo T; D'Angelo S; Valentini G
Clin Exp Rheumatol; 2004; 22(2):145-50. PubMed ID: 15083880
[TBL] [Abstract][Full Text] [Related]
5. Type III procollagen N-terminal propeptide, soluble interleukin-2 receptor, and von Willebrand factor in systemic sclerosis.
Lee YJ; Shin KC; Kang SW; Lee EB; Kim HA; Song YW
Clin Exp Rheumatol; 2001; 19(1):69-74. PubMed ID: 11247328
[TBL] [Abstract][Full Text] [Related]
6. Androgen and prolactin (Prl) levels in systemic sclerosis (SSc): relationship to disease severity.
Mirone L; Barini A; Barini A
Ann N Y Acad Sci; 2006 Jun; 1069():257-62. PubMed ID: 16855152
[TBL] [Abstract][Full Text] [Related]
7. Dehydroepiandrosterone sulfate is positively correlated with soluble interleukin 2 receptor and soluble intercellular adhesion molecule in systemic lupus erythematosus.
Straub RH; Zeuner M; Antoniou E; Schölmerich J; Lang B
J Rheumatol; 1996 May; 23(5):856-61. PubMed ID: 8724298
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of soluble TNF alpha receptor type I and the severity of systemic sclerosis.
Majewski S; Wojas-Pelc A; Malejczyk M; Szymanska E; Jablonska S
Acta Derm Venereol; 1999 May; 79(3):207-10. PubMed ID: 10384918
[TBL] [Abstract][Full Text] [Related]
9. Prolactin and thyroid hormones in patients with systemic sclerosis: correlations with disease manifestations and activity.
Shahin AA; Abdoh S; Abdelrazik M
Z Rheumatol; 2002 Dec; 61(6):703-9. PubMed ID: 12491136
[TBL] [Abstract][Full Text] [Related]
10. Altered diurnal rhythm of prolactin in systemic sclerosis.
Hilty C; Brühlmann P; Sprott H; Gay RE; Michel BA; Gay S; Neidhart M
J Rheumatol; 2000 Sep; 27(9):2160-5. PubMed ID: 10990228
[TBL] [Abstract][Full Text] [Related]
11. Dehydroepiandrosterone sulphate in critical illness: effect of dopamine.
Van den Berghe G; de Zegher F; Wouters P; Schetz M; Verwaest C; Ferdinande P; Lauwers P
Clin Endocrinol (Oxf); 1995 Oct; 43(4):457-63. PubMed ID: 7586621
[TBL] [Abstract][Full Text] [Related]
12. Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement.
Kuryliszyn-Moskal A; Klimiuk PA; Sierakowski S
Clin Rheumatol; 2005 Apr; 24(2):111-6. PubMed ID: 15349798
[TBL] [Abstract][Full Text] [Related]
13. Soluble serum interleukin 2 receptors in patients with systemic sclerosis.
Steen VD; Engel EE; Charley MR; Medsger TA
J Rheumatol; 1996 Apr; 23(4):646-9. PubMed ID: 8730120
[TBL] [Abstract][Full Text] [Related]
14. Soluble adhesion molecules and cytokines in patients with myasthenia gravis treated by plasma exchange.
Tesar V; Jelínková E; Jirsa M; Bakosová M; Pitha P; Chábová V
Blood Purif; 2000; 18(2):115-20. PubMed ID: 10838470
[TBL] [Abstract][Full Text] [Related]
15. Evaluating serum prolactin and serum dehydroepiandrosterone sulfate levels in patients with pemphigus.
Yousefi M; Mozafari N; Hosseini MS; Gholamin S; Razavi SM; Namazi MR; Younespour S
Int J Dermatol; 2016 Jun; 55(6):e332-7. PubMed ID: 26910580
[TBL] [Abstract][Full Text] [Related]
16. Association of humoral markers of inflammation and dehydroepiandrosterone sulfate or cortisol serum levels in patients with chronic inflammatory bowel disease.
Straub RH; Vogl D; Gross V; Lang B; Schölmerich J; Andus T
Am J Gastroenterol; 1998 Nov; 93(11):2197-202. PubMed ID: 9820396
[TBL] [Abstract][Full Text] [Related]
17. Increased levels of circulating intercellular adhesion molecule-1 in patients with systemic sclerosis.
Kiener H; Graninger W; Machold K; Aringer M; Graninger WB
Clin Exp Rheumatol; 1994; 12(5):483-7. PubMed ID: 7842528
[TBL] [Abstract][Full Text] [Related]
18. [Soluble receptors of cytokines in sera of patients with systemic sclerosis--clinical correlation].
Lis AD; Brzezińska-Wcisło LA
Wiad Lek; 2003; 56(11-12):532-6. PubMed ID: 15058159
[TBL] [Abstract][Full Text] [Related]
19. A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels.
Polisson RP; Gilkeson GS; Pyun EH; Pisetsky DS; Smith EA; Simon LS
J Rheumatol; 1996 Apr; 23(4):654-8. PubMed ID: 8730122
[TBL] [Abstract][Full Text] [Related]
20. Circulating soluble adhesion molecules in patients with systemic sclerosis: correlation between circulating soluble vascular cell adhesion molecule-1 (sVCAM-1) and impaired left ventricular diastolic function.
Shahin AA; Anwar S; Elawar AH; Sharaf AE; Hamid MA; Eleinin AA; Eltablawy M
Rheumatol Int; 2000 Dec; 20(1):21-4. PubMed ID: 11149656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
